Clinical TrialAug 11, 2026, 08:32 AM
RenovoRx Completes Enrollment in Phase III TIGeR-PaC Trial
AI Summary
RenovoRx, Inc. announced the completion of enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer (LAPC) as of August 7, 2026. The trial, which evaluates intra-arterial gemcitabine (IAG) via RenovoCath, is expected to be completed in the first half of 2027, with initial top-line data anticipated in the second half of 2027. This milestone reflects successful patient recruitment and clinical execution for a therapy targeting a significant unmet medical need.
Key Highlights
- Completed enrollment in Phase III TIGeR-PaC trial for LAPC as of August 7, 2026.
- Trial completion expected during the first half of 2027.
- Initial top-line trial data expected during the second half of 2027.
- Trial requires 86 events (patient deaths); 78 events have occurred as of August 11, 2026.
- RenovoCath sales were $1.1 million in 2025 and $563,000 in Q1 2026.
Price Impact
More from RNXT